Actively Recruiting
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-11-06
109
Participants Needed
2
Research Sites
574 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient. The study will explore the use of an imaging agent called hyperpolarized \[1-13C\] pyruvate (HP) with MRI scans. (MRI) is a technique that takes pictures of the body's organs using a magnetic field and radiofrequency waves that cannot be felt. In order to accomplish the goal of the study the patient will have two hyperpolarized MRI scans to assess if scans can be reproduced. The hyperpolarized MRI scans will be compared with the pathological results of the surgery to see if the hyperpolarized MRI provides additional information regarding disease metabolism.
CONDITIONS
Official Title
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of histologically confirmed malignant solid tumor (confirmed by MSKCC Department of Pathology). An exception applies to patients with brain lesions highly suspicious for neoplasm by MRI features without histological confirmation.
- Tumor measurable or evaluable by RECIST 1.1 or other MSKCC-approved criteria, with a mass greater than 1 cm in the long axis.
- Negative serum or urine pregnancy test for female patients of childbearing potential within 2 weeks prior to enrollment.
- Patients with sarcoma, prostate, breast, brain, metastatic, or pancreatic cancer are eligible. Other patient groups may be included in the future by protocol amendment.
You will not qualify if you...
- Unable or unwilling to have at least one peripheral intravenous line for pyruvate injection.
- Breast-feeding.
- Unable or unwilling to tolerate MRI scanning (e.g., due to claustrophobia).
- Liver function abnormalities: bilirubin > 1.5 times upper limit of normal (ULN), AST/ALT > 2.5 times ULN, albumin < 3 g/dl, GGT > 2.5 times ULN if alkaline phosphatase > 2.5 times ULN.
- Kidney function abnormalities: creatinine > 1.5 times ULN or creatinine clearance < 60 mL/min.
- Acute major illness such as unstable cardiovascular conditions.
- Standard MRI exclusions including pacemakers or metal clips in the patient.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Memorial Sloan Kettering Bergen (Consent only )
Montvale, New Jersey, United States, 07645
Actively Recruiting
2
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
K
Kayvan Keshari, PhD
CONTACT
V
Vesselin Miloushev, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here